CommercialCoverageLow impact
08.01.26d, Enzyme Replacement Therapy for Adenosine Deaminase Severe Combined Immune Deficiency (e.g., elapegademase-lvlr [Revcovi])
Independence Blue Cross·Pediatrics, Allergy & Immunology, Infectious Disease·Medical Policy
Effective date
Nov 26, 2025
We identified it
Jun 19, 2026
Summary
This policy reissue (effective 11/26/2025) addresses coverage and clinical criteria for enzyme replacement therapy using elapegademase-lvlr (Revcovi) for patients with adenosine deaminase severe combined immune deficiency (ADA-SCID). The billing team must ensure claims for this rare genetic disorder therapy comply with the updated policy requirements, including any prior authorization mandates and documentation standards specific to this specialized treatment.
Action Required
By 11/26/2025: Billing team must review the full policy text at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=11&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-01-26d to identify specific CPT/HCPCS codes, prior authorization requirements, and clinical documentation standards for elapegademase-lvlr claims. Update billing system rules, prior authorization workflows, and provider communications accordingly. Verify that all claims for ADA-SCID enzyme replacement therapy comply with the reissued criteria to avoid denials. Note: No specific billing codes were provided in the policy summary; obtain the complete policy document to extract exact codes and requirements.